For more than two decades, we are providing comprehensive pharmaceutical analytical services to clients across the industry. Our services include method verification, development and validation, impurity identification and characterizations and isolation of impurities by preparative scale purification, reverse phase/normal phase, ion-exchange or gel filtration chromatographic techniques. Our analytical team works in close collaboration with our process chemistry team to ensure that every method suits the process requirements for raw materials, APIs and formulations.
Our pharmaceutical analytical services research team is well versed with current regulatory requirements to support you from early research to market.
We offer method verification, development and validation for excipients, raw materials, APIs and drug products including high potent compounds, steroids, carbohydrates and synthetic peptides.
Our Custom Services also Include:
- Purity of Enantiomers
- Identification of related substances and assay
- Method development for non-chromophoric compounds
- Fate and purge studies
- Genotoxic Impurity (GTI) studies
- Impurity isolation and characterization
- Assay, dissolution, content uniformity and impurities content studies
Analytical instruments
- HPLC with VWD, DAD, ELSD, CAD and RID
- UPLC with VWD and DAD
- LC-MS/MS triple quard
- LCMS-TOF
- GC and GC-HS
- GC-MS (EI/CI MSD)
- Ion Chromatography
- ICP-OES
- AB Sciex QTRAP 4500 Mass Spec
- NMR 400 MHz
- Amino Acid Analyzer
- Dissolution: USP type I and type II, small volume dissolutions using USP Type II apparatus and in-vitro diffusion cell apparatus
- UV-VIS Spectrophotometer
- FT-IR Spectrophotometer
- Polarimeter
- Auto-titrator and KF Apparatus
- Differential Scanning Calorimeter
- Thermo Gravimetric Analyser
- Particle Size Analyser (Malvern)
- Nano-particle Size Analyser (zeta sizer)
Aurigene Pharmaceutical Services is
a leading CDMO/CRO
that provides contract research and manufacturing services
FAQ
- Analytical method development, method validation, and method transfer of Key Starting Materials ( KSM), Intermediates and drug substance. We also have experience in developing and validating following analytical methods.
- Purity/Related substances/Assay by HPLC
- Purity/Related substances/Assay by GC
- Residual solvents by GC/GC-HS
- Impurity profiling by HPLC/GC/LC-MS/GC-MS
- Identification and characterization, quantification of impurities by LC-MS/GC-MS & NMR
- Trace level elemental impurities identification and quantification by ICP-MS
- Genotoxic impurities
- Cleaning method development and validation
- Holding study/stability studies
- Hygroscopic study (EP/USP)
- Melting point determination/identification of different polymorphs/determination of Glass transition temperatures by DSC
- Safety studies for the reaction mass samples by DSC
- Thermogravimetric analysis for the samples (TGA)
- Trace level ions determination by Ion chromatography
- Particles size distribution (PSD)
- Purification/isolation of impurities and characterization
- Purification/isolation of desired compounds
- Amino acids analysis
- Peptide analysis
- CMC activities (establishment of Physico-chemical properties for the regulatory submission)
- Testing of raw materials
- Testing of in-process samples
- Testing of intermediates
- Testing of drug substance
| <1225>&<1226> | US Pharmacopoeia chapter |
| CDER Guidance | Guideline for Submitting Samples and Analytical Data for Methods Validation. February 1987. |
| CDER Reviewer Guidance | Validation of Chromatographic methods. November 19 |
| ICH Q2 (R1) | Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonization |
| ICH Q6A | Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, International Conference on Harmonization. |
| ICH Q7 | GMP Guidance for Active Pharmaceutical Ingredients, International Conference on Harmonization. |
| RDC.N°17 | Good Practices for medicament manufacturing |
| RDC.N°53 | “Establishes parameters for reporting, identification and qualification of degradation products in synthetic drugs with active substances and semi-synthetic classified as new, generic and the like, and other measures”. |
| RE.N°166 | Guide for validation of Analytical and Bio-analytical methods |
| USP General chapters | General tests and assays. |
- HPLCs with wide range of detectors (UV, PDA, CAD, RID and ELSD), Waters and Agilent
- GC with Headspace and FID, Agilent make
- GC-MS Agilent make (model: 5975C)
- LC-MS- AB Sciex QTRAP 4500
- UPLC-TOF, Waters
- ICP-MS- Agilent make (model: 7800)
- Ion chromatography, Metrohm
- FT-IR, spectrum one, Perkin Elmer make (model: spectrum one)
- Polarimeter, Jasco (model P2000)
- Karl-Fisher apparatus, Metrohm
- Auto titrator, Metrohm
- Differential scanning calorimeter (DSC), TA (model: TA DSC Q 2000)
- Thermo gravimetric analyzer (TGA), TA
- Particle size analyzer, Master sizer 3000
- Amino acid analyzer, Sykam
Virtual Tour
Contact Us
Other Services
- Custom Carbohydrate Synthesis
- Custom Library Synthesis
- Custom Peptide Synthesis
- Early Phase Development and Kilo Lab Facility
- Medicinal Chemistry Services
- Methoxy PEGs
- Oligonucleotide Synthesis Services
- PROTAC Synthesis & Screening for Targeted Protein Degradation
- Solid Phase Peptide Synthesis Services
- Synthetic Chemistry Services
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.